Atezolizumab (atezo) plus bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis Meeting Abstract
| Authors: | Rini, B. I.; Motzer, R. J.; Powles, T.; McDermott, D. F.; Escudier, B.; Donskov, F.; Hawkins, R. E.; Bracarda, S.; Bedke, J.; De Giorgi, U.; Porta, C.; Ravaud, A.; Parnis, F.; Grande, E.; Zhang, W.; Huseni, M. A.; Carroll, S.; Sufan, R. I.; Schiff, C.; Atkins, M. B. |
| Abstract Title: | Atezolizumab (atezo) plus bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 267s |
| Language: | English |
| ACCESSION: | WOS:000487345805338 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.4512 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4512 -- Source: Wos |
